Bioventix BVXP ShareSoc Richmond 6 6 16
Peter Harrison CEO Bioventix (BVXP)
ShareSoc Richmond 6.6.16
A succinct presentation to understand what BVXP do.
• The product
• Revenue streams
• Stickiness of revenue
• Timelines to develop revenue streams
• Barriers to entry
• The future
A sense of the culture of the company
The journey of the historic research that led to current products.
The pipeline of future products.
Peter Harrison is a 12% shareholder, Miton 14.5% and other institutional holders
Q&A at 38:55, with questions around possible threats covering:
• Impact of loss of NT proBNP, and replacement of revenues by Troponin
• Technological threats
• Time it’s taken to get Treponin to market
• The future of company
• Personalise medicine
• Collaborations with other organisations
Videos from Bioventix